Highlights Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Market Closed - Hong Kong S.E. Other stock markets 08:08:30 22/11/2023 GMT			5-day change	1st Jan Change
5.62 ^HKD	-0.71%		-.--%	-.--%

06-14	Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S	CI
06-14	Venus Medtech (Hangzhou) Implants First Patient with VenusP-Valve in US Clinical Study	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S	06-14	CI
Venus Medtech (Hangzhou) Implants First Patient with VenusP-Valve in US Clinical Study	06-14	MT
Venus Medtech Board Receives Internal Control Review Report from Consultant	05-13	MT
Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%	04-01	MT
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action	11-28	MT
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China	11-22	MT
Venus Medtech's H1 Attributable Loss Widens	01/09/23	MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23	CI
US FDA Grants Clinical Trial Approval to Venus Medtech's Pulmonary Valve Replacement	07/08/23	MT
Venus Medtech Inc. Announces it's Self-Developed Transcatheter Pulmonary Valve Replacement System VenusP-Valve Received the Approval of IDE (Investigational Device Exemption) Application from the US Food and Drug Administration	06/08/23	CI
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Venus Medtech Inc. Announces Completion of Full Patient Enrollment for Confirmatory Clinical Trial of Liwen RF in China	03/03/23	CI
China to Exclude Medical Devices From Bulk-Buying Program	07/09/22	MT
Venus Medtech (Hangzhou)'s H1 Loss Widens 76.8%	01/09/22	MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	31/08/22	CI
China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System	13/07/22	CI
Chinese Regulator Approves Venus Medtech's Valve Replacement System	13/07/22	MT
Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use	22/06/22	CI
Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product	13/04/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Highlights

Filters